{"name":"Shanghai Hutchison Pharmaceuticals Limited","slug":"shanghai-hutchison-pharmaceuticals-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SHPL-49 Injection","genericName":"SHPL-49 Injection","slug":"shpl-49-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"MUSK pill","genericName":"MUSK pill","slug":"musk-pill","indication":"Treatment of glaucoma","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Shenqi Sherong Pill","genericName":"Shenqi Sherong Pill","slug":"shenqi-sherong-pill","indication":"Fatigue, weakness, and shortness of breath in patients with chronic heart failure","status":"phase_3"}]}],"pipeline":[{"name":"SHPL-49 Injection","genericName":"SHPL-49 Injection","slug":"shpl-49-injection","phase":"phase_3","mechanism":"SHPL-49 Injection is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"MUSK pill","genericName":"MUSK pill","slug":"musk-pill","phase":"marketed","mechanism":"MUSK pill works by inhibiting the activity of the muscarinic acetylcholine receptor.","indications":["Treatment of glaucoma"],"catalyst":""},{"name":"Shenqi Sherong Pill","genericName":"Shenqi Sherong Pill","slug":"shenqi-sherong-pill","phase":"phase_3","mechanism":"Shenqi Sherong Pill is a traditional Chinese medicine formula used to enhance the body's Qi and promote overall health.","indications":["Fatigue, weakness, and shortness of breath in patients with chronic heart failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9DeXB6T2lLQ3RXUWI0T1MxQklsTDNta3NIV2pSb3k3d2t5UlBZeS16RlZ5MWpTM0VoNlFsTGU2dWhYaEN3R2hGaG1oQnJ3RzRFX2V5VnJpaVZLV3VrVWdjSHZadlFVeloyem80b9IBckFVX3lxTFBBSWcxMG93NjFtV2lBNUEzM0kxZFRpamxqbmtsZG1PN0hSQzlYQzkyUWtpUlU0QTZOQmp5VVFmWThVdVRpOXlDZHRGNFZIRjUyRVkwcXo0cWFNdjl0M3lVUFpjdW8yZjU5X1RNZFBRTW1qUQ?oc=5","date":"2025-01-03","type":"pipeline","source":"Pulse 2.0","summary":"HUTCHMED Sells $608 Million Stake In SHPL - Pulse 2.0","headline":"HUTCHMED Sells $608 Million Stake In SHPL - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOT052UEk4N3dKanpLVHF1NEYtQVdCSnpxOFdfX2dkX1laTkhwWWhtZ25Pb2lGaE4yQXAtbkVscVpBT0JoY1BHWVg5U0k5aTZfZ3JuSVAyanNLeDlzRG5WVmZTOURRcG85TFowcjNsbVlBckY5UzBVWHFQSFVVTFpReEcyTnlZSEJ1MjdkUzB0eGtpOTRTcmJ4Qw?oc=5","date":"2025-01-02","type":"pipeline","source":"Fierce Pharma","summary":"With $608M divestment, Hutchmed continues to focus on ADC development - Fierce Pharma","headline":"With $608M divestment, Hutchmed continues to focus on ADC development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE4yMkNXa1lWcVowUWFfU0VtX3JQOHM5YkJtOEl2aUVncklxMzhoaHY4ME8wby1Gby1WenZSemZaQ3h4ZlNfRDlneGVwM2lIQWFjUy1zUlFtZm1GNjlTWldWQVY4cFloSXU0RnJmSnUxSV8xTVkt?oc=5","date":"2025-01-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"HUTCHMED to divest 45% equity interest in SHPL for $608m - Pharmaceutical Technology","headline":"HUTCHMED to divest 45% equity interest in SHPL for $608m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOWlNkOWhVVzJRNDdMbDBGRkpLejhSYnlqcHdKdHBTeldSYzZQWW55TjF2a1BrbkVvUzBwSDZseXBVN3R0bkF0VFZISHpLVEU1Q0w4el9OLTFwUjAtNTFMMk02MUFsM1Vsd3FFRHNRNks3ZVlkeVl1RzNBbjdlbGdsbFJYbUdjaENDdlU5YmNOV09vOXFUVVktYXhQSQ?oc=5","date":"2025-01-02","type":"regulatory","source":"CHEManager","summary":"Hutchmed to Divest Stake in Joint Venture for $608 Million - CHEManager","headline":"Hutchmed to Divest Stake in Joint Venture for $608 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOMzhGQlF2YTYwR243cEprd3JDbUplNFZHQ2V5cG11LVVqMGQ0NmZFVUxTX1AxZnJjSUd5LS1xYjg1RG0xVTNuVFNQXzRlMTEtTkdXY3VFd1VOc0tmS21GbUxXUUV1QklueTI3d0xqRFdpMW1NYkZneEljUTlXY2pCNnhDdUpiUQ?oc=5","date":"2025-01-02","type":"pipeline","source":"pharmaphorum","summary":"Hutchmed cashes in a Chinese JV to help fund its pipeline - pharmaphorum","headline":"Hutchmed cashes in a Chinese JV to help fund its pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQdFpSXzFTWE5TNklXbzB3dGJ6MU90WkdxVldXYnRzb29xcHdocEQydHY1UTBFNDVfaHROMm9kV1k0RWxZNjNzWGJxUkpnVWNKbzItVGFzdTNFc3B6alRMRkctN0hHZFgtQkxBeEduOW5hUVBNdFlneFNCRmo1R0FodTBDM2ZtaERXVkE?oc=5","date":"2025-01-02","type":"pipeline","source":"The Standard (HK)","summary":"Hutchmed divests from venture - The Standard (HK)","headline":"Hutchmed divests from venture - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNczZLeXhPbzBSNzctRVk3RjUwWlZlZHlucmQzRl9hMGpiWWxnV3dkTnZ1eWdveVAwb09PMmJXMzJKOG1PdnNlS1ItcTFEZFMyVjdoWXluUm1tRlRQS3BBSUhBcUtkZDFEbkhkOTdPeml1dEFKbjdRQmpJdEZ3QmhMalVsMWx4eUJvYmNBU08tTGtGWXJCWDd3ckoybXZydjVJQnhoN190cTFvckhaWHdZbS1QNWszdlp6SmlUSHdMNUF3NmJ0anc0VF9LMnFfZkdBcVRySVFkU2FFWTRWUHJQampTRGktWTloa2lwZjRNZlg2Wk1EdDM1cTIxaw?oc=5","date":"2025-01-01","type":"pipeline","source":"Quiver Quantitative","summary":"HUTCHMED Announces Divestment of 45% Stake in Shanghai Hutchison Pharmaceuticals to Focus on Innovative Medicines and R&D Pipeline - Quiver Quantitative","headline":"HUTCHMED Announces Divestment of 45% Stake in Shanghai Hutchison Pharmaceuticals to Focus on Innovative Medicines and R&","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQRjRubmRVT19PVEtvc0ZzVF9PaElyWDlVYTlxRUdGbmZMN2s1XzdUajNPLU1Galp6ZEZtamVWRDA2Ul9TcHR2TllEQmFXWWgybkxLRkRNS083Umdxb1k0X3F0WlBabHNuYmZYdUJUSzZZNlFadkNWSDlKaEx2ZHAtN3J0bmc4Z2oyaE5Bc2IzVnVab1cya3BPdFRadlBWRThPRGtsRFdRT1VxV3QxeHNSanNqcDc?oc=5","date":"2025-01-01","type":"pipeline","source":"Bloomberg.com","summary":"Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million - Bloomberg.com","headline":"Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE0wa1NwcVBRQU52V0JlM3lGVndiRVNnQnNZVnBiRThmVl8yTjZQSS01VXlzUk9TeURzUktKa3VMM1lGc0hwUFZUX1FIUjU4U2hEbzJoVTVUUnR3eTBK?oc=5","date":"2024-11-02","type":"pipeline","source":"Site Selection Magazine","summary":"Shanghai’s Beauty Spot - Site Selection Magazine","headline":"Shanghai’s Beauty Spot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNdW5vMUV0YWk1T3RncTJLcWZZc1VKWWJBSjNkeDJRRG5DWGwyZHg5WGoxMUVrb0xLNHBPOXVqbjdRNzFhNGtOaE1FTjVBUC1HMGdxTmROaWNoQmhucUhzQ01SNGozdWVicXBXSFkxUzhiTnAyVEhWM1ZfU1E1dXJudFdqa1l3aE9va2NITUMyRUZVQzBM?oc=5","date":"2023-05-17","type":"trial","source":"Frontiers","summary":"Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine - Frontiers","headline":"Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNTmtpYURaVEhPYkNqc0FkczdWaHNyQXpkVXRSaVRUT0RDTm42bDQ1N1d3eDh6ZXd6czdkVGdPak5IbGxaekROMEduQnJ2LUdzMFJpbTNyVlRuVDBQMmxHbFZFTlBOS3JvbkgwMVYxSEJnenNnU0dvaF9yUDMtTmxjcXVMeWRxX1hMZ3hTcXdVdFpGM0tUYjFmdHIxbDh4OE5iTVlBQ3Q4V2JyY0g1cWpnZmdzV21yMktObTJNMmY3X2FBQ2R0aXBKbEtOOElkdS1iSnd3SGNRWHNlYzdVT3VBTkh4cklVU0dsaWF2dlhmUnZKNmRBLUplLVhpSm8tODJnNVdHVWlxQUR3U1ZIRVFxYVdPczVMSXhxOGc?oc=5","date":"2023-05-10","type":"pipeline","source":"PR Newswire","summary":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsight - PR Newswire","headline":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPT0U1ZXNoZmtGN0RJS1h0M1NTRUx2Qm96bjk3RmRSSUN2N05CQTh3T29Kc0k2clVXQXZLN1BhSktJb1M1bm03YTg2a1FxbW1UTk5md2lHWXFDR2xWMVlaMjB3STZSdDRXeUVvQWZGa29rdURLNjU0RllnenRJSXVoQURvQzVPemJCa1kwLUJKMXlnRkRuOUNjcGFQNTZSNURUNi1zMWtXUzZNdWN5aW9fMUpVR2w0UnZNQnM4andMZmE?oc=5","date":"2018-03-04","type":"pipeline","source":"Reuters","summary":"China's Tasly to list biotech arm in $1 billion Hong Kong IPO - sources - Reuters","headline":"China's Tasly to list biotech arm in $1 billion Hong Kong IPO - sources","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}